【中国生物：国药集团已对药材股份侵权和不正当竞争行为向公安机关依法报案】金十数据2月12日讯，近日，国药药材股份有限公司及其所属企业多次出现法律纠纷案件，发生拖欠施工单位甚至农村集体企业款项事件，中国医药集团有限公司也时常接到投诉信函。国药集团声明如下：自2016年11月起，国药集团下属中国中药有限公司在药材股份的持股比例为25%。对药材股份，国药集团、国药中药既非控股股东、也非实际控制人。对药材股份涉嫌侵害国药集团商标权和不正当竞争行为，国药集团、国药中药已依法提起诉讼；对药材股份虚构股东大会会议，伪造股东大会决议、伪造国药中药董事签字、伪造变造公司章程等违法行为，国药中药已依法提起诉讼并获法院支持；对药材股份伪造印章等涉嫌犯罪行为，已向公安机关依法报案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.